2024
Maternal Bereavement and Heart Failure Risk of the Offspring
Goldstein S, Pastor T, Samsky M. Maternal Bereavement and Heart Failure Risk of the Offspring. JACC Heart Failure 2024, 12: 1363-1364. PMID: 39111951, DOI: 10.1016/j.jchf.2024.06.002.Peer-Reviewed Original Research
2021
Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
Greene SJ, Choi S, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, Hammill BG, Luo N, Samsky MD, Heidenreich PA, Laskey WK, Yancy CW, Peterson PN, Curtis LH, Hernandez AF, Fonarow GC, O'Brien EC. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal Of The American Heart Association 2021, 10: e021459. PMID: 34350772, PMCID: PMC8475054, DOI: 10.1161/jaha.121.021459.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsDrug CombinationsFemaleHeart FailureHospitalizationHumansMaleMedicareNeprilysinPatient DischargeProtease InhibitorsRegistriesRisk AssessmentRisk FactorsStroke VolumeTime FactorsTreatment OutcomeUnited StatesValsartanVentricular Function, LeftConceptsEnzyme inhibitors/angiotensin II receptor blockersSacubitril/valsartanAngiotensin II receptor blockersII receptor blockersHeart failure hospitalizationReduced ejection fractionCause hospitalizationReceptor blockersFailure hospitalizationCause mortalityOlder patientsDischarge prescriptionsEjection fractionHeart failureAngiotensin-converting enzyme inhibitors/angiotensin II receptor blockersGuidelines-Heart Failure registryRoutine US clinical practiceMedicare beneficiaries ageUS clinical practiceHFrEF medicationsPostdischarge mortalityPostdischarge outcomesClinical outcomesRandomized trialsClinical effectiveness
2017
Assessment of cardiac allograft systolic function by global longitudinal strain: From donor to recipient
DeVore AD, Alenezi F, Krishnamoorthy A, Ersboll M, Samsky MD, Schulte PJ, Patel CB, Rogers JG, Milano CA, Velazquez EJ, Khouri MG. Assessment of cardiac allograft systolic function by global longitudinal strain: From donor to recipient. Clinical Transplantation 2017, 31: e12961. PMID: 28294407, DOI: 10.1111/ctr.12961.Peer-Reviewed Original ResearchConceptsLV global longitudinal strainLeft ventricular ejection fractionGlobal longitudinal strainMedian left ventricular ejection fractionSystolic functionLongitudinal strainLV systolic dysfunctionMyocardial systolic performancePost-transplant outcomesLV systolic functionVentricular ejection fractionDonor-recipient pairsMyocardial deformation analysisAllograft dysfunctionCardiac allograftsCause hospitalizationSystolic dysfunctionPretransplant levelsEjection fractionSystolic performanceCorresponding recipientsClinical implicationsRecipientsEchocardiogramFurther studies
2016
Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support
Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuzat M, Testani JM, Wang TS, Verma A, Samsky MD, Donahue MP, Ilkayeva OR, Bowles DE, Patel CB, Milano CA, Rogers JG, Felker GM, O’Connor C, Shah SH, Kraus WE. Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. Journal Of The American College Of Cardiology 2016, 67: 291-299. PMID: 26796394, PMCID: PMC5429585, DOI: 10.1016/j.jacc.2015.10.079.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarnitineDisease ProgressionEnergy MetabolismExercise TherapyFemaleHeart Failure, SystolicHeart-Assist DevicesHospital MortalityHumansMaleMass SpectrometryMiddle AgedNorth CarolinaOutcome Assessment, Health CarePrognosisReproducibility of ResultsSeverity of Illness IndexStatistics as TopicConceptsEnd-stage heart failureSystolic heart failureHeart failureMechanical circulatory supportHF patientsClinical outcomesCirculatory supportEnd-stage systolic heart failureChronic systolic HF patientsLeft ventricular assist device placementLong-term mechanical circulatory supportVentricular assist device placementPeak VO2 levelsChronic HF patientsSystolic HF patientsAdverse clinical outcomesClinical trial outcomesLong-chain acylcarnitinesAssociations of metabolitesFrozen plasma samplesMechanical circulatoryCardiovascular deathCause hospitalizationCause mortalityLVAD group
2014
Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, Fluid Homeostasis, Inflammation, and Renal Injury
Ahmad T, Wang T, O'Brien EC, Samsky MD, Pura JA, Lokhnygina Y, Rogers JG, Hernandez AF, Craig D, Bowles DE, Milano CA, Shah SH, Januzzi JL, Felker GM, Patel CB. Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, Fluid Homeostasis, Inflammation, and Renal Injury. JACC Heart Failure 2014, 3: 30-39. PMID: 25447345, DOI: 10.1016/j.jchf.2014.06.013.Peer-Reviewed Original ResearchConceptsVentricular assist device supportC-reactive proteinAssist device supportRenal injuryHeart failureGalectin-3LVAD therapyAmino-terminal pro-B-type natriuretic peptideNeutrophil Gelatinase-Associated Lipocalin LevelsDevice supportPro-B-type natriuretic peptideContinuous-flow LVAD implantationLeft ventricular assist device supportAdvanced heart failureNT-proBNP concentrationsGrowth differentiation factorLipocalin levelsHs-CRPNT-proBNPGDF-15LVAD implantationLVAD placementMedian ageNatriuretic peptideMyocardial recovery